In the BioHarmony Drug Report Database

"Preview" Icon

Obinutuzumab

Gazyva, Gazyvaro (obinutuzumab) is an antibody pharmaceutical. Obinutuzumab was first approved as Gazyva on 2013-11-01. It is used to treat follicular lymphoma and lymphoid leukemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia. The pharmaceutical is active against B-lymphocyte antigen CD20.

 

Trade Name

 

Gazyvaro
 

Common Name

 

obinutuzumab
 

ChEMBL ID

 

CHEMBL1743048
 

Indication

 

b-cell chronic lymphocytic leukemia, follicular lymphoma, lymphoid leukemia
 

Drug Class

 

Monoclonal antibodies: humanized, tumors as target

Image (chem structure or protein)

Obinutuzumab structure rendering